Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase 4 2Phase NA 1Phase 3 1

Status

Completed 10Unknown 3Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Specimen Handling 5Enoxaparin 5Carboplatin 5Bevacizumab 5Nivolumab 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Imatinib Mesylate × Clear all
NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03844360 2025-03-30

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Shandong University

Phase 4 Recruiting
1,500 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡